jollibee 6 pcs www jilibet.com jollibee breakfast menu ubet casino login jolibet 3 login
Current location: jilibet slots > jollibee 6 pcs > vb777

vb777

Release time: 2025-01-22 | Source: Unknown
Reports: Bill Belichick interviews for North Carolina jobWARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") WINT , a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. "The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities," said Craig Fraser, Chairman and CEO. "With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements," Mr. Fraser added. "Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization." Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company's Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company's common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient's condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, "Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, "Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF)." The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company's business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff ("Staff") of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q ("Form 10-Q") for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company's Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the Company's ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov . Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.com WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES Consolidated Balance Sheets (in thousands, except share and per share data) September 30, 2024 December 31, 2023 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 2,300 $ 4,319 Prepaid expenses and other current assets 1,628 1,060 Total current assets 3,928 5,379 Property and equipment, net 128 183 Restricted cash 9 150 Operating lease right-of-use assets 1,133 1,444 Intangible assets 25,250 25,250 Total assets $ 30,448 $ 32,406 LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 2,054 $ 809 Accrued expenses 1,650 1,618 Operating lease liabilities - current portion 468 436 ELOC commitment note payable 317 - Derivative liability - ELOC commitment note 347 - Common stock warrant liability 8,621 - Loans payable 444 233 Other current liabilities 525 900 Total current liabilities 14,426 3,996 Operating lease liabilities - non-current portion 784 1,161 Restructured debt liability - contingent milestone payments - 15,000 Other liabilities 3,800 3,800 Deferred tax liabilities 4,887 5,058 Total liabilities 23,897 29,015 Mezzanine Equity: Series C redeemable preferred stock, $0.001 par value; 18,820 and 0 shares authorized; 15,719 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 2,142 - Series B redeemable preferred stock, $0.001 par value; 5,500 and 0 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively - - Total mezzanine equity 2,142 - Stockholders' Equity: Preferred stock, $0.001 par value; 4,975,680 and 5,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively - - Common stock, $0.001 par value; 120,000,000 shares authorized; 2,340,429 and 333,145 shares issued at September 30, 2024 and December 31, 2023, respectively; 2,340,428 and 333,144 shares outstanding at September 30, 2024 and December 31, 2023, respectively 2 - Additional paid-in capital 856,267 851,268 Accumulated deficit (848,806 ) (844,823 ) Treasury stock (at cost); 1 share (3,054 ) (3,054 ) Total stockholders' equity 4,409 3,391 Total liabilities, mezzanine equity & stockholders' equity $ 30,448 $ 32,406 WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Expenses: Research and development $ 1,968 $ 2,110 $ 14,084 $ 5,288 General and administrative 2,773 2,580 6,514 7,292 Loss on impairment of goodwill - - - 3,058 Total operating expenses 4,741 4,690 20,598 15,638 Operating loss (4,741 ) (4,690 ) (20,598 ) (15,638 ) Other income (expense): Gain on debt extinguishment 71 - 14,591 - Change in fair value of common stock warrant liability 2,166 - 2,166 - Interest income 12 112 62 264 Interest expense (51 ) (13 ) (174 ) (38 ) Other (expense) income, net (446 ) 166 (530 ) 275 Total other income, net 1,752 265 16,115 501 Loss before income taxes (2,989 ) (4,425 ) (4,483 ) (15,137 ) Income tax benefit (expense) 240 - (71 ) - Net loss $ (2,749 ) $ (4,425 ) $ (4,554 ) $ (15,137 ) Extinguishment of Series B Preferred Stock 572 - 572 - Deemed dividend on Series C Preferred Stock (1,573 ) - (1,573 ) - Net loss attributable to common stockholders $ (3,750 ) $ (4,425 ) $ (5,555 ) $ (15,137 ) Net loss per share attributable to common stockholders Basic and diluted $ (4.23 ) $ (15.47 ) $ (8.64 ) $ (80.95 ) Weighted average number of common shares outstanding Basic and diluted 887 286 643 187 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.More Than Just the Always Pan: Our Place's 7 Must-Shop Kitchen Essentialsvb777 。

Steelers QB Russell Wilson is spreading the wealth on offense

NEW YORK , Dec. 10, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Macy's, Inc. (NYSE: M) resulting from allegations that Macy's may have issued materially misleading business information to the investing public. So What: If you purchased Macy's securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=31645 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. What is this about: On November 25, 2024 , The New York Times published an article entitled "Macy's Discovers Employee Hid Millions in Delivery Expenses." This article stated that "Macy's said on Monday that an employee had "intentionally" misstated and hidden up to $154 million in delivery expenses over the past few years, forcing the retailer to delay a much-anticipated earnings report that Wall Street uses to gauge the strength of holiday shopping." On this news, the price of Macy's, Inc. stock fell 2.2% on November 25, 2024 . Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia: https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-macys-inc-investors-to-inquire-about-securities-class-action-investigation--m-302327927.html SOURCE THE ROSEN LAW FIRM, P. A. Stay Informed: Subscribe to Our Newsletter Today

Mikaela Shiffrin suffers abrasion on hip during crash on final run of World Cup giant slalomThe AP Top 25 college football poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . OKLAHOMA CITY (AP) — Alabama faces a tougher roadblock than it might appear in its quest to maintain positioning for the College Football Playoff. Sure, Oklahoma has struggled in its first Southeastern Conference season. The Sooners (5-5, 1-5 SEC) have lost four straight conference games. The Sooners have fired their offensive coordinator and they have the worst offense in the league. But they have a tough defense, too. Linebacker Danny Stutsman, a midseason AP All-American, anchors a nasty unit that has kept the Sooners competitive in losses at Ole Miss and Missouri. He ranks second in the SEC with 96 tackles. Defensive back Billy Bowman Jr. has scored four defensive touchdowns since the start of the 2023 season, tied for the most nationally. Defensive end R Mason Thomas has seven sacks, with six coming in the fourth quarter of close games. Alabama coach Kalen DeBoer is paying attention. “It’s going to take a great week of preparation,” DeBoer said. “A physical football team all around. Their defense is, I think, an extremely tough defense in all ways — just what they do with their scheme and then with their personnel, the way they fly around.” RELATED COVERAGE Coach Spencer Danielson says 12th-ranked Boise State must seize moment and respect 2-win Wyoming No. 12 Boise State heads to Wyoming hoping to maintain No. 4 seed in College Football Playoff No. 4 Penn State tries to keep playoff picture out of focus in prep for tough trip to Minnesota Plus, Oklahoma is motivated. It’s Senior Day for a program that would become bowl eligible with a win. Beating the seventh-ranked Crimson Tide could cure a lot of ills for the Sooners. “I think they know they could be a great example for what fight and what belief and what finishing and what improving and what proving people wrong looks like,” Oklahoma coach Brent Venables said. “And I think this is a group of guys that are committed to doing that.” Alabama (8-2, 4-2) has more answers than most. Jalen Milroe has passed for 15 touchdowns and rushed for 17. Freshman receiver Ryan Williams has 40 catches for 767 yards and eight touchdowns. “Yeah, incredibly explosive, and they have great playmakers everywhere,” Venables said. “Certainly, it starts — everything goes through the quarterback.” There has been much talk about what a third loss would do to Alabama’s playoff hopes. DeBoer said his team isn’t focused on that. “I think we’re really honed in and the guys really believe on and have understood the significance of really focusing on where we’re at right now,” he said. “We talk about the next play is the most important play, the next game is the most important game. We haven’t thought about anything beyond Oklahoma.” Heisman hype Milroe is only the fourth SEC quarterback since 2007 to have at least 15 passing touchdowns and 17 rushing touchdowns in a single season. The others won the Heisman Trophy during their seasons — Florida’s Tim Tebow in 2007, Auburn’s Cam Newton in 2010 and Texas A&M’s Johnny Manziel in 2012. “I think it just starts with doing what’s best for the team, and that’s what Jalen is all about,” DeBoer said. Arnold’s improvement Since returning to the lineup early against South Carolina four games ago, Oklahoma quarterback Jackson Arnold has completed 70 of 112 passes for 705 yards with five touchdowns with no interceptions. Still, his fumble that was returned for a touchdown in the final minute against Missouri was the difference in a 30-23 loss. Arnold has dealt with significant criticism all season. “That goes along with that position at a place like the University of Oklahoma,” Venables said. “That’s a position that’s a little bit ... it’s a bit like the head coach position. There’s a different type of microscope and there’s a different type of focus and that’s okay he’s got broad shoulders to handle that.” Questionable Barnes Oklahoma running back Jovantae Barnes ran for career highs of 203 yards and three touchdowns against Maine two weeks ago, then he sat out last week’s loss to Missouri. He’s listed as questionable on this week’s injury report. He leads the Sooners with 577 yards rushing this season. Stepping in Venables is impressed with what DeBoer has done in his first year at Alabama since taking over for Nick Saban. “One of Kalen’s strengths as a football coach — a very successful coach — is he takes a group of players that he has, and their staff figures out what they can do,” Venables said. “They major in that, put them in position to be successful based on the players’ strengths. They’ve done a nice job of doing that throughout the course of the season.” Big games Oklahoma beat heavily favored Alabama 45-31 in the Sugar Bowl to cap the 2013 season, a game that helped pump energy into the Sooner program under Bob Stoops. Alabama got revenge in 2018, beating the Sooners 45-34 in the College Football Playoff. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

Rams in search of offensive consistency in New OrleansNoneThe U.S. Navy is transforming a costly flub into a potent weapon with the first shipborne hypersonic weapon, which is being retrofitted aboard the first of its three stealthy destroyers. The USS Zumwalt is at a Mississippi shipyard where workers have installed missile tubes that replace twin turrets from a gun system that was never activated because it was too expensive. Once the system is complete, the Zumwalt will provide a platform for conducting fast, precision strikes from greater distances, adding to the usefulness of the warship. The USS Zumwalt is seen at the Huntington Ingalls shipyard Nov. 21 in Pascagoula, Miss. “It was a costly blunder. But the Navy could take victory from the jaws of defeat here, and get some utility out of them by making them into a hypersonic platform,” said Bryan Clark, a defense analyst at the Hudson Institute. The U.S. has had several types of hypersonic weapons in development for the past two decades, but recent tests by both Russia and China have added pressure to the U.S. military to hasten their production. Hypersonic weapons travel beyond Mach 5, five times the speed of sound, with added maneuverability making them harder to shoot down. Last year, The Washington Post reported that among the documents leaked by former Massachusetts Air National Guard member Jack Teixeira was a defense department briefing that confirmed China had recently tested an intermediate-range hypersonic weapon called the DF-27. While the Pentagon previously acknowledged the weapon's development, it had not recognized its testing. One of the U.S. programs in development and planned for the Zumwalt is the “Conventional Prompt Strike." It would launch like a ballistic missile and then release a hypersonic glide vehicle that would travel at speeds seven to eight times faster than the speed of sound before hitting the target. The weapon system is being developed jointly by the Navy and Army. Each of the Zumwalt-class destroyers would be equipped with four missile tubes, each with three of the missiles for a total of 12 hypersonic weapons per ship. In choosing the Zumwalt, the Navy is attempting to add to the usefulness of a $7.5 billion warship that is considered by critics to be an expensive mistake despite serving as a test platform for multiple innovations. The USS Zumwalt is seen at the Huntington Ingalls shipyard Nov. 21 in Pascagoula, Miss. The Zumwalt was envisioned as providing land-attack capability with an Advanced Gun System with rocket-assisted projectiles to open the way for Marines to charge ashore. But the system featuring 155 mm guns hidden in stealthy turrets was canceled because each of the rocket-assisted projectiles cost between $800,000 and $1 million. Despite the stain on its reputation, the three Zumwalt-class destroyers remain the Navy’s most advanced surface warship in terms of new technologies. Those innovations include electric propulsion, an angular shape to minimize radar signature, an unconventional wave-piercing hull, automated fire and damage control and a composite deckhouse that hides radar and other sensors. The Zumwalt arrived at the Huntington Ingalls Industries shipyard in Pascagoula, Mississippi, in August 2023 and was removed from the water for the complex work of integrating the new weapon system. It is due to be undocked this week in preparation for the next round of tests and its return to the fleet, shipyard spokeswoman Kimberly Aguillard said. A U.S. hypersonic weapon was successfully tested over the summer and development of the missiles is continuing. The Navy wants to begin testing the system aboard the Zumwalt in 2027 or 2028, according to the Navy. The U.S. weapon system will come at a steep price. It would cost nearly $18 billion to buy 300 of the weapons and maintain them over 20 years, according to the Congressional Budget Office. Critics say there is too little bang for the buck. “This particular missile costs more than a dozen tanks. All it gets you is a precise non-nuclear explosion, some place far far away. Is it really worth the money? The answer is most of the time the missile costs much more than any target you can destroy with it,” said Loren Thompson, a longtime military analyst in Washington, D.C. The U.S. Navy intercepted Houthi missiles and drones targeting two warships and three merchant vessels in the Gulf of Aden. But they provide the capability for Navy vessels to strike an enemy from a distance of thousands of kilometers — outside the range of most enemy weapons — and there is no effective defense against them, said retired Navy Rear Adm. Ray Spicer, CEO of the U.S. Naval Institute, an independent forum focusing on national security issues, and former commander of an aircraft carrier strike force. Conventional missiles that cost less aren’t much of a bargain if they are unable to reach their targets, Spicer said, adding the U.S. military really has no choice but to pursue them. “The adversary has them. We never want to be outdone,” he said. The U.S. is accelerating development because hypersonics have been identified as vital to U.S. national security with “survivable and lethal capabilities,” said James Weber, principal director for hypersonics in the Office of the Assistant Secretary of Defense for Critical Technologies. “Fielding new capabilities that are based on hypersonic technologies is a priority for the defense department to sustain and strengthen our integrated deterrence, and to build enduring advantages,” he said. Image Credit: Jacob Lund / Shutterstock The financial challenges facing U.S. military households are a significant concern throughout the year. Holidays such as Memorial Day, Armed Forces Day, or Veterans Day highlight the ongoing struggles that service members face, particularly amid rising costs for everyday essentials. Recent data from the U.S. Census Bureau’s Household Pulse Survey shows a troubling trend: Military personnel and their families are finding it more difficult to cover basic household expenses such as food, housing, and transportation than the average American. Our analysis examines how service members are faring in today’s economy compared to civilian households, highlighting the states where military families report the greatest challenges in managing their finances. As we enter Giving Season, we’ve also highlighted meaningful ways to support service members and their families through charitable contributions, offering an opportunity to make a direct impact on those who serve our nation. Service members are struggling more financially than the average American. Image Credit: Upgraded Points According to recent Household Pulse Survey data, members of the armed services are experiencing financial strain at higher rates than the general U.S. population. Over 40% of service members report difficulty covering their usual household expenses, compared to 36.6% of all U.S. adults. The data also shows heightened anxiety among service members regarding rising prices. Nearly 80% of military personnel express stress about recent price increases, significantly higher than the 71.8% of all U.S. adults who share similar feelings. Furthermore, 81.8% of service members are concerned about future price hikes, reflecting widespread uncertainty about inflation’s long-term impact on household budgets. More than half of service members in certain states have difficulty covering basic household expenses. Image Credit: Upgraded Points Across the U.S., the financial burden on service members varies significantly from state to state, primarily influenced by local economic conditions. According to the most recent data, Utah leads with 53.7% of service members reporting difficulty covering basic household expenses, closely followed by Louisiana (52.9%) and Alaska (52.8%). Other states where over half of service members are struggling include Indiana (52.0%), Tennessee (51.2%), New York (50.8%), and Florida (50.3%). A key issue service members frequently raise is that their Basic Allowance for Housing (BAH) has not kept pace with the rapidly rising cost of housing. In states where service members face the greatest financial difficulties, such as Utah, Indiana, Tennessee, and Florida, home price increases have far exceeded the national average, exacerbating the strain on household budgets. Another critical factor affecting military families is the employment challenges military spouses face. According to the Department of Defense, the military spouse unemployment rate was 21% in 2023, compared to a national rate of 3.6% that year. Many military bases are located in rural or remote areas, limiting job opportunities for spouses, particularly in specialized fields. Additionally, frequent relocations make it difficult for spouses to sustain long-term careers, especially for those in professions requiring state-specific occupational licenses that can be difficult to transfer. Service members are also more likely to report financial struggles in states with higher-than-average unemployment rates, such as Louisiana, Alaska, and New York. Conversely, the state unemployment rate is below average in 9 of the 10 states where service members report the least financial difficulty. This suggests that strong local employment opportunities, particularly for spouses, significantly ease the financial burden on military households. Photo Credit: Bumble Dee / Shutterstock One of the most impactful ways to support service members, veterans, and their families who are facing financial hardships is through donations to reputable charities. These organizations are dedicated to addressing the unique challenges faced by military families and veterans, providing vital assistance in areas like housing, medical expenses, scholarships, and career training. To help guide your generosity, we’ve compiled a list of top-rated charities based on scores from Charity Navigator , CharityWatch , and GuideStar , which assess organizations on criteria such as impact, efficiency, accountability, and transparency. Here are some of the best charities supporting military families and veterans in need: 1. USO For over 80 years, the USO has provided crucial support to active-duty service members and their families. From financial assistance programs to community-building initiatives, the USO helps service members stay connected to loved ones while addressing their most pressing needs during deployments and transitions. 2. Homes For Our Troops This charity is focused on providing specially adapted homes for severely injured post-9/11 veterans. It helps veterans regain independence. Homes For Our Troops also provides financial planning and household budgeting to ensure long-term stability for the recipients. 3. Iraq and Afghanistan Veterans of America (IAVA) Dedicated to advocating for veterans of the Iraq and Afghanistan wars, IAVA works to improve government policies and programs that support military families. Its advocacy ensures veterans have access to financial resources, healthcare, and education opportunities. 4. Fisher House Foundation This foundation builds “comfort homes” near military and VA medical centers, allowing families to stay free of charge while a loved one is hospitalized. By reducing travel and lodging expenses, Fisher House eases financial stress during difficult times. 5. Hope For The Warriors Offering a range of programs focused on financial stability, wellness, social support, and education, Hope For The Warriors provides critical support to service members, veterans, and their families. Its services include direct financial assistance for transitioning service members and veterans in need, career training and job placement, and scholarships for spouses. 6. Semper Fi & America’s Fund Semper Fi & America’s Fund assists wounded, ill, and injured service members and their families through direct financial assistance and case management during hospitalization and recovery. The organization also provides educational support, career assistance, and health and wellness services. 7. Wounded Warriors Family Support (WWFS) WWFS supports families of those wounded or killed in combat through programs like medical travel grants, meal and housekeeping assistance, in-home care services, and family retreats. By addressing these families' immediate and ongoing needs, WWFS alleviates the financial burdens of those suffering from recent tragic events. For more information, a detailed methodology, and complete results, see Rising Costs Hit Military Families Hard: Here’s How You Can Help on Upgraded Points . Photo Credit: Jacob Lund / Shutterstock Upgraded Points conducted the analysis using the latest data from the U.S. Census Bureau Household Pulse Survey Phase 4.0–4.2 , covering the period from January 9, 2024, to September 16, 2024. Service members were defined as adults currently serving in the U.S. armed forces (Active Duty, Reserve, or National Guard) and their spouses. This analysis focuses on 3 key questions from the survey: Statistics with fewer than 50 survey responses were omitted from the analysis. Additional statistics on home prices were sourced from Zillow’s Home Value Index , and unemployment rates were sourced from the U.S. Census Bureau’s 2023 American Community Survey 1-Year Estimates . For complete results, see Rising Costs Hit Military Families Hard: Here’s How You Can Help on Upgraded Points. We're always interested in hearing about news in our community. Let us know what's going on! Get local news delivered to your inbox!

Sikh high priests stare at example of Gurbachan Singh

Sandstorm Gold Royalties Provides Updates on Producing and Key Development Assets

Reports: Bill Belichick interviews for North Carolina jobWARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") WINT , a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions, today reported financial results for the third quarter ended September 30, 2024 and provided key business updates. "The third quarter of 2024 was marked with significant progress. We were very pleased with the SEISMiC B study results in early cardiogenic shock showing significant improvement in many measures of cardiac function and blood pressure along with a favorable safety profile in patients with heart failure and cardiogenic shock. There have been four positive Phase 2 studies with over 300 patients treated with istaroxime resulting in a consistent, unique and attractive drug profile across a wide range of severities," said Craig Fraser, Chairman and CEO. "With trial execution and active operations comes the need for capital and we successfully completed transactions providing resources for our near-term needs as well as secured an equity line of credit to potentially support future requirements," Mr. Fraser added. "Looking forward, we plan to accelerate enrollments in the istaroxime SCAI Stage C cardiogenic shock study with a planned interim data read out in early Q2 2025 as well as providing guidance on our strategy and planned activities with our oncology preclinical aPKCi inhibitor assets. Given what we believe to be strong data and market need, the Company is turning attention to business development activities to secure additional licenses and partnerships for our multi-asset cardiovascular platform with the objective to secure non-dilutive capital and partner resources to advance the assets to potential commercialization." Key Business Updates Announced positive Phase 2b topline clinical results with istaroxime significantly improving cardiac function and blood pressure in heart failure patients with early cardiogenic shock. The study met its primary endpoint in significantly improving systolic blood pressure over six hours (SBP AUC) for the combined Part A and Part B SEISMiC istaroxime group compared to placebo as well as for SEISMiC Part B alone. The improvements in SBP AUC at 24 hours were also significantly increased by istaroxime and the improvements were sustained through 96 hours of measurement. Cardiac output (the amount of blood pumped by the heart over a minute) and filling pressures in the heart significantly improved as did measured kidney function. Heart failure severity as assessed by the NYHA classification decreased significantly up to 72 hours compared to placebo. A favorable safety and tolerability profile, including risk for cardiac arrythmias, was also observed. The clinical study data was presented in a late-breaker session at the Heart Failure Society of America conference and the Company reviewed the clinical results along with the program strategy and plans at a virtual Investor Meeting which has been posted to the Company website. Completed two private placements in July 2024 for aggregate proceeds of approximately $13.9 million, which consisted of approximately $4.4 million of new funding (with $2.3 million of net proceeds) and a $9.5 million payment through the full cancellation and extinguishment of certain holders outstanding senior notes, including secured notes, and shares of the Company's Series B Convertible Preferred Stock. Entered into a Common Stock Purchase Agreement with an equity line investor, whereby the Company has the right, but not the obligation, to sell such investor, and, subject to limited exceptions, the investor is obligated to purchase for up to $35 million of newly issued shares of the Company's common stock. Announced initiation of the SEISMiC C study of istaroxime in SCAI Stage C cardiogenic shock to complete Phase 2b and advance the transition to Phase 3. This is a global trial including sites in the U.S., Europe and Latin America. It is a placebo-controlled, double-blinded study with istaroxime being added to current standard of care with inotropes and/or vasopressors. The effect of istaroxime in addition to these therapies will be assessed for 6 hours and based on the patient's condition, the ability to remove standard of care therapies while on istaroxime will also be assessed. The primary endpoint of the study is assessment of systolic blood pressure (SBP) profile over the first 6 hours of treatment. Expanded patent estate with new patents with istaroxime in cardiogenic shock and acute heart failure. Cardiogenic shock national phase filings were completed for patent applications around the world, including in the United States, Germany, France, Italy, Japan and China. A patent was issued for istaroxime for Japan entitled, "Istaroxime-containing intravenous formulation for the treatment of heart failure and it has been accorded Patent No. 7560134. A patent was issued for istaroxime for Hong Kong, and it is entitled, "Istaroxime-containing intravenous formulation for the treatment of heart failure (AHF)." The claims are directed formulations comprising istaroxime, pharmaceutically acceptable salts thereof, and methods of use, alone, or in combination with other agents useful for the treatment and management of acute heart failure. Select Third Quarter 2024 Financial Results For the third quarter ended September 30, 2024, the Company reported an operating loss of $4.7 million, which was comparable to an operating loss of $4.7 million in the third quarter of 2023. Included in our operating loss for the third quarter of 2024 is $2.2 million related to the change in fair value of our common stock warrant liability and $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. Research and development expenses were $2.0 million for the third quarter of 2024, compared to $2.1 million for the third quarter of 2023. Research and development expenses for both periods primarily relate to the SEISMiC Extension trial of istaroxime for the treatment of early cardiogenic shock which completed enrollment during the third quarter of 2024. General and administrative expenses for the third quarter of 2024 were $2.8 million, compared to $2.6 million for the third quarter of 2023. For the third quarter of 2024, general and administrative expenses include $0.7 million in expenses related to the two private placements completed in July 2024 which were allocated to the warrants issued in those transactions and expensed immediately. The Company reported a net loss attributable to common stockholders of $3.8 million ($4.23 per basic share) on 0.9 million weighted-average common shares outstanding for the quarter ended September 30, 2024, compared to a net loss of $4.4 million ($15.47 per basic share) on 0.3 million weighted average common shares outstanding for the comparable period in 2023. As of September 30, 2024, the Company reported cash and cash equivalents of $2.3 million and current liabilities of $14.4 million, which includes an $8.6 million warrant liability. Included in prepaid expenses and other assets as of September 30, 2024 is $0.7 million in receivables related to ELOC Purchase Agreement gross proceeds for sales made during the quarter for which we had not yet received the cash payment. The related net proceeds after the redemption of the Series C Preferred Stock was $0.5 million. In addition, subsequent to September 30, 2024 and through November 22, 2024, we sold an additional 4.3 million shares of Common Stock under the ELOC Purchase Agreement for net proceeds of $2.4 million following mandatory redemption payments on our Series C Preferred Stock. Following these financings, we believe that we have sufficient resources available to fund our business operations through January 2025. Readers are referred to, and encouraged to read in its entirety, the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, which was filed with the Securities and Exchange Commission on November 26, 2024, and includes detailed discussions about the Company's business plans and operations, financial condition, and results of operations. Nasdaq Update On November 21, 2024, the Company received a letter from the Nasdaq Listing Qualifications Staff ("Staff") of The Nasdaq Stock Market LLC stating that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of it not having timely filed its Quarterly Report on Form 10-Q ("Form 10-Q") for the quarter ended September 30, 2024 with the Securities and Exchange Commission. Based on the November 26, 2024 filing of the Company's Form 10-Q and a subsequent letter received from Nasdaq on November 27, 2024 stating the Staff has determined that the Company complies with Nasdaq Listing Rule 5250(c)(1), this matter is now closed. About Windtree Therapeutics, Inc. Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Windtree's portfolio of product candidates includes istaroxime, a Phase 2 candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Windtree also has a licensing business model with partnership out-licenses currently in place. Forward Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Examples of such risks and uncertainties include, among other things: the Company's ability to secure significant additional capital as and when needed; the Company's ability to achieve the intended benefits of the aPKCi asset acquisition with Varian Biopharmaceuticals, Inc.; the Company's risks and uncertainties associated with the success and advancement of the clinical development programs for istaroxime and the Company's other product candidates, including preclinical oncology candidates; the Company's ability to access the debt or equity markets; the Company's ability to manage costs and execute on its operational and budget plans; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; risks related to technology transfers to contract manufacturers and manufacturing development activities; delays encountered by the Company, contract manufacturers or suppliers in manufacturing drug products, drug substances, and other materials on a timely basis and in sufficient amounts; risks relating to rigorous regulatory requirements, including that: (i) the U.S. Food and Drug Administration or other regulatory authorities may not agree with the Company on matters raised during regulatory reviews, may require significant additional activities, or may not accept or may withhold or delay consideration of applications, or may not approve or may limit approval of the Company's product candidates, and (ii) changes in the national or international political and regulatory environment may make it more difficult to gain regulatory approvals and risks related to the Company's efforts to maintain and protect the patents and licenses related to its product candidates; risks that the Company may never realize the value of its intangible assets and have to incur future impairment charges; risks related to the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates, if approved; the Company's ability to maintain compliance with the continued listing requirements of Nasdaq; the economic and social consequences of the COVID-19 pandemic and the impacts of political unrest, including as a result of geopolitical tension, including the conflict between Russia and Ukraine, the People's Republic of China and the Republic of China (Taiwan), and the evolving events in the Middle East, and any sanctions, export controls or other restrictive actions that may be imposed by the United States and/or other countries which could have an adverse impact on the Company's operations, including through disruption in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which could have an adverse impact on the Company's ability to access the capital markets. These and other risks are described in the Company's periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov . Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Contact Information: Eric Curtis ecurtis@windtreetx.com WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES Consolidated Balance Sheets (in thousands, except share and per share data) September 30, 2024 December 31, 2023 (Unaudited) ASSETS Current Assets: Cash and cash equivalents $ 2,300 $ 4,319 Prepaid expenses and other current assets 1,628 1,060 Total current assets 3,928 5,379 Property and equipment, net 128 183 Restricted cash 9 150 Operating lease right-of-use assets 1,133 1,444 Intangible assets 25,250 25,250 Total assets $ 30,448 $ 32,406 LIABILITIES, MEZZANINE EQUITY & STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 2,054 $ 809 Accrued expenses 1,650 1,618 Operating lease liabilities - current portion 468 436 ELOC commitment note payable 317 - Derivative liability - ELOC commitment note 347 - Common stock warrant liability 8,621 - Loans payable 444 233 Other current liabilities 525 900 Total current liabilities 14,426 3,996 Operating lease liabilities - non-current portion 784 1,161 Restructured debt liability - contingent milestone payments - 15,000 Other liabilities 3,800 3,800 Deferred tax liabilities 4,887 5,058 Total liabilities 23,897 29,015 Mezzanine Equity: Series C redeemable preferred stock, $0.001 par value; 18,820 and 0 shares authorized; 15,719 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 2,142 - Series B redeemable preferred stock, $0.001 par value; 5,500 and 0 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively - - Total mezzanine equity 2,142 - Stockholders' Equity: Preferred stock, $0.001 par value; 4,975,680 and 5,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively - - Common stock, $0.001 par value; 120,000,000 shares authorized; 2,340,429 and 333,145 shares issued at September 30, 2024 and December 31, 2023, respectively; 2,340,428 and 333,144 shares outstanding at September 30, 2024 and December 31, 2023, respectively 2 - Additional paid-in capital 856,267 851,268 Accumulated deficit (848,806 ) (844,823 ) Treasury stock (at cost); 1 share (3,054 ) (3,054 ) Total stockholders' equity 4,409 3,391 Total liabilities, mezzanine equity & stockholders' equity $ 30,448 $ 32,406 WINDTREE THERAPEUTICS, INC. AND SUBSIDIARIES Consolidated Statements of Operations (in thousands, except per share data) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Expenses: Research and development $ 1,968 $ 2,110 $ 14,084 $ 5,288 General and administrative 2,773 2,580 6,514 7,292 Loss on impairment of goodwill - - - 3,058 Total operating expenses 4,741 4,690 20,598 15,638 Operating loss (4,741 ) (4,690 ) (20,598 ) (15,638 ) Other income (expense): Gain on debt extinguishment 71 - 14,591 - Change in fair value of common stock warrant liability 2,166 - 2,166 - Interest income 12 112 62 264 Interest expense (51 ) (13 ) (174 ) (38 ) Other (expense) income, net (446 ) 166 (530 ) 275 Total other income, net 1,752 265 16,115 501 Loss before income taxes (2,989 ) (4,425 ) (4,483 ) (15,137 ) Income tax benefit (expense) 240 - (71 ) - Net loss $ (2,749 ) $ (4,425 ) $ (4,554 ) $ (15,137 ) Extinguishment of Series B Preferred Stock 572 - 572 - Deemed dividend on Series C Preferred Stock (1,573 ) - (1,573 ) - Net loss attributable to common stockholders $ (3,750 ) $ (4,425 ) $ (5,555 ) $ (15,137 ) Net loss per share attributable to common stockholders Basic and diluted $ (4.23 ) $ (15.47 ) $ (8.64 ) $ (80.95 ) Weighted average number of common shares outstanding Basic and diluted 887 286 643 187 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.More Than Just the Always Pan: Our Place's 7 Must-Shop Kitchen Essentialsvb777 。

Steelers QB Russell Wilson is spreading the wealth on offense

NEW YORK , Dec. 10, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Macy's, Inc. (NYSE: M) resulting from allegations that Macy's may have issued materially misleading business information to the investing public. So What: If you purchased Macy's securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=31645 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. What is this about: On November 25, 2024 , The New York Times published an article entitled "Macy's Discovers Employee Hid Millions in Delivery Expenses." This article stated that "Macy's said on Monday that an employee had "intentionally" misstated and hidden up to $154 million in delivery expenses over the past few years, forcing the retailer to delay a much-anticipated earnings report that Wall Street uses to gauge the strength of holiday shopping." On this news, the price of Macy's, Inc. stock fell 2.2% on November 25, 2024 . Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm , on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/ . Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 case@rosenlegal.com www.rosenlegal.com View original content to download multimedia: https://www.prnewswire.com/news-releases/rosen-law-firm-encourages-macys-inc-investors-to-inquire-about-securities-class-action-investigation--m-302327927.html SOURCE THE ROSEN LAW FIRM, P. A. Stay Informed: Subscribe to Our Newsletter Today

Mikaela Shiffrin suffers abrasion on hip during crash on final run of World Cup giant slalomThe AP Top 25 college football poll is back every week throughout the season! Get the poll delivered straight to your inbox with AP Top 25 Poll Alerts. Sign up here . OKLAHOMA CITY (AP) — Alabama faces a tougher roadblock than it might appear in its quest to maintain positioning for the College Football Playoff. Sure, Oklahoma has struggled in its first Southeastern Conference season. The Sooners (5-5, 1-5 SEC) have lost four straight conference games. The Sooners have fired their offensive coordinator and they have the worst offense in the league. But they have a tough defense, too. Linebacker Danny Stutsman, a midseason AP All-American, anchors a nasty unit that has kept the Sooners competitive in losses at Ole Miss and Missouri. He ranks second in the SEC with 96 tackles. Defensive back Billy Bowman Jr. has scored four defensive touchdowns since the start of the 2023 season, tied for the most nationally. Defensive end R Mason Thomas has seven sacks, with six coming in the fourth quarter of close games. Alabama coach Kalen DeBoer is paying attention. “It’s going to take a great week of preparation,” DeBoer said. “A physical football team all around. Their defense is, I think, an extremely tough defense in all ways — just what they do with their scheme and then with their personnel, the way they fly around.” RELATED COVERAGE Coach Spencer Danielson says 12th-ranked Boise State must seize moment and respect 2-win Wyoming No. 12 Boise State heads to Wyoming hoping to maintain No. 4 seed in College Football Playoff No. 4 Penn State tries to keep playoff picture out of focus in prep for tough trip to Minnesota Plus, Oklahoma is motivated. It’s Senior Day for a program that would become bowl eligible with a win. Beating the seventh-ranked Crimson Tide could cure a lot of ills for the Sooners. “I think they know they could be a great example for what fight and what belief and what finishing and what improving and what proving people wrong looks like,” Oklahoma coach Brent Venables said. “And I think this is a group of guys that are committed to doing that.” Alabama (8-2, 4-2) has more answers than most. Jalen Milroe has passed for 15 touchdowns and rushed for 17. Freshman receiver Ryan Williams has 40 catches for 767 yards and eight touchdowns. “Yeah, incredibly explosive, and they have great playmakers everywhere,” Venables said. “Certainly, it starts — everything goes through the quarterback.” There has been much talk about what a third loss would do to Alabama’s playoff hopes. DeBoer said his team isn’t focused on that. “I think we’re really honed in and the guys really believe on and have understood the significance of really focusing on where we’re at right now,” he said. “We talk about the next play is the most important play, the next game is the most important game. We haven’t thought about anything beyond Oklahoma.” Heisman hype Milroe is only the fourth SEC quarterback since 2007 to have at least 15 passing touchdowns and 17 rushing touchdowns in a single season. The others won the Heisman Trophy during their seasons — Florida’s Tim Tebow in 2007, Auburn’s Cam Newton in 2010 and Texas A&M’s Johnny Manziel in 2012. “I think it just starts with doing what’s best for the team, and that’s what Jalen is all about,” DeBoer said. Arnold’s improvement Since returning to the lineup early against South Carolina four games ago, Oklahoma quarterback Jackson Arnold has completed 70 of 112 passes for 705 yards with five touchdowns with no interceptions. Still, his fumble that was returned for a touchdown in the final minute against Missouri was the difference in a 30-23 loss. Arnold has dealt with significant criticism all season. “That goes along with that position at a place like the University of Oklahoma,” Venables said. “That’s a position that’s a little bit ... it’s a bit like the head coach position. There’s a different type of microscope and there’s a different type of focus and that’s okay he’s got broad shoulders to handle that.” Questionable Barnes Oklahoma running back Jovantae Barnes ran for career highs of 203 yards and three touchdowns against Maine two weeks ago, then he sat out last week’s loss to Missouri. He’s listed as questionable on this week’s injury report. He leads the Sooners with 577 yards rushing this season. Stepping in Venables is impressed with what DeBoer has done in his first year at Alabama since taking over for Nick Saban. “One of Kalen’s strengths as a football coach — a very successful coach — is he takes a group of players that he has, and their staff figures out what they can do,” Venables said. “They major in that, put them in position to be successful based on the players’ strengths. They’ve done a nice job of doing that throughout the course of the season.” Big games Oklahoma beat heavily favored Alabama 45-31 in the Sugar Bowl to cap the 2013 season, a game that helped pump energy into the Sooner program under Bob Stoops. Alabama got revenge in 2018, beating the Sooners 45-34 in the College Football Playoff. ___ Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

Rams in search of offensive consistency in New OrleansNoneThe U.S. Navy is transforming a costly flub into a potent weapon with the first shipborne hypersonic weapon, which is being retrofitted aboard the first of its three stealthy destroyers. The USS Zumwalt is at a Mississippi shipyard where workers have installed missile tubes that replace twin turrets from a gun system that was never activated because it was too expensive. Once the system is complete, the Zumwalt will provide a platform for conducting fast, precision strikes from greater distances, adding to the usefulness of the warship. The USS Zumwalt is seen at the Huntington Ingalls shipyard Nov. 21 in Pascagoula, Miss. “It was a costly blunder. But the Navy could take victory from the jaws of defeat here, and get some utility out of them by making them into a hypersonic platform,” said Bryan Clark, a defense analyst at the Hudson Institute. The U.S. has had several types of hypersonic weapons in development for the past two decades, but recent tests by both Russia and China have added pressure to the U.S. military to hasten their production. Hypersonic weapons travel beyond Mach 5, five times the speed of sound, with added maneuverability making them harder to shoot down. Last year, The Washington Post reported that among the documents leaked by former Massachusetts Air National Guard member Jack Teixeira was a defense department briefing that confirmed China had recently tested an intermediate-range hypersonic weapon called the DF-27. While the Pentagon previously acknowledged the weapon's development, it had not recognized its testing. One of the U.S. programs in development and planned for the Zumwalt is the “Conventional Prompt Strike." It would launch like a ballistic missile and then release a hypersonic glide vehicle that would travel at speeds seven to eight times faster than the speed of sound before hitting the target. The weapon system is being developed jointly by the Navy and Army. Each of the Zumwalt-class destroyers would be equipped with four missile tubes, each with three of the missiles for a total of 12 hypersonic weapons per ship. In choosing the Zumwalt, the Navy is attempting to add to the usefulness of a $7.5 billion warship that is considered by critics to be an expensive mistake despite serving as a test platform for multiple innovations. The USS Zumwalt is seen at the Huntington Ingalls shipyard Nov. 21 in Pascagoula, Miss. The Zumwalt was envisioned as providing land-attack capability with an Advanced Gun System with rocket-assisted projectiles to open the way for Marines to charge ashore. But the system featuring 155 mm guns hidden in stealthy turrets was canceled because each of the rocket-assisted projectiles cost between $800,000 and $1 million. Despite the stain on its reputation, the three Zumwalt-class destroyers remain the Navy’s most advanced surface warship in terms of new technologies. Those innovations include electric propulsion, an angular shape to minimize radar signature, an unconventional wave-piercing hull, automated fire and damage control and a composite deckhouse that hides radar and other sensors. The Zumwalt arrived at the Huntington Ingalls Industries shipyard in Pascagoula, Mississippi, in August 2023 and was removed from the water for the complex work of integrating the new weapon system. It is due to be undocked this week in preparation for the next round of tests and its return to the fleet, shipyard spokeswoman Kimberly Aguillard said. A U.S. hypersonic weapon was successfully tested over the summer and development of the missiles is continuing. The Navy wants to begin testing the system aboard the Zumwalt in 2027 or 2028, according to the Navy. The U.S. weapon system will come at a steep price. It would cost nearly $18 billion to buy 300 of the weapons and maintain them over 20 years, according to the Congressional Budget Office. Critics say there is too little bang for the buck. “This particular missile costs more than a dozen tanks. All it gets you is a precise non-nuclear explosion, some place far far away. Is it really worth the money? The answer is most of the time the missile costs much more than any target you can destroy with it,” said Loren Thompson, a longtime military analyst in Washington, D.C. The U.S. Navy intercepted Houthi missiles and drones targeting two warships and three merchant vessels in the Gulf of Aden. But they provide the capability for Navy vessels to strike an enemy from a distance of thousands of kilometers — outside the range of most enemy weapons — and there is no effective defense against them, said retired Navy Rear Adm. Ray Spicer, CEO of the U.S. Naval Institute, an independent forum focusing on national security issues, and former commander of an aircraft carrier strike force. Conventional missiles that cost less aren’t much of a bargain if they are unable to reach their targets, Spicer said, adding the U.S. military really has no choice but to pursue them. “The adversary has them. We never want to be outdone,” he said. The U.S. is accelerating development because hypersonics have been identified as vital to U.S. national security with “survivable and lethal capabilities,” said James Weber, principal director for hypersonics in the Office of the Assistant Secretary of Defense for Critical Technologies. “Fielding new capabilities that are based on hypersonic technologies is a priority for the defense department to sustain and strengthen our integrated deterrence, and to build enduring advantages,” he said. Image Credit: Jacob Lund / Shutterstock The financial challenges facing U.S. military households are a significant concern throughout the year. Holidays such as Memorial Day, Armed Forces Day, or Veterans Day highlight the ongoing struggles that service members face, particularly amid rising costs for everyday essentials. Recent data from the U.S. Census Bureau’s Household Pulse Survey shows a troubling trend: Military personnel and their families are finding it more difficult to cover basic household expenses such as food, housing, and transportation than the average American. Our analysis examines how service members are faring in today’s economy compared to civilian households, highlighting the states where military families report the greatest challenges in managing their finances. As we enter Giving Season, we’ve also highlighted meaningful ways to support service members and their families through charitable contributions, offering an opportunity to make a direct impact on those who serve our nation. Service members are struggling more financially than the average American. Image Credit: Upgraded Points According to recent Household Pulse Survey data, members of the armed services are experiencing financial strain at higher rates than the general U.S. population. Over 40% of service members report difficulty covering their usual household expenses, compared to 36.6% of all U.S. adults. The data also shows heightened anxiety among service members regarding rising prices. Nearly 80% of military personnel express stress about recent price increases, significantly higher than the 71.8% of all U.S. adults who share similar feelings. Furthermore, 81.8% of service members are concerned about future price hikes, reflecting widespread uncertainty about inflation’s long-term impact on household budgets. More than half of service members in certain states have difficulty covering basic household expenses. Image Credit: Upgraded Points Across the U.S., the financial burden on service members varies significantly from state to state, primarily influenced by local economic conditions. According to the most recent data, Utah leads with 53.7% of service members reporting difficulty covering basic household expenses, closely followed by Louisiana (52.9%) and Alaska (52.8%). Other states where over half of service members are struggling include Indiana (52.0%), Tennessee (51.2%), New York (50.8%), and Florida (50.3%). A key issue service members frequently raise is that their Basic Allowance for Housing (BAH) has not kept pace with the rapidly rising cost of housing. In states where service members face the greatest financial difficulties, such as Utah, Indiana, Tennessee, and Florida, home price increases have far exceeded the national average, exacerbating the strain on household budgets. Another critical factor affecting military families is the employment challenges military spouses face. According to the Department of Defense, the military spouse unemployment rate was 21% in 2023, compared to a national rate of 3.6% that year. Many military bases are located in rural or remote areas, limiting job opportunities for spouses, particularly in specialized fields. Additionally, frequent relocations make it difficult for spouses to sustain long-term careers, especially for those in professions requiring state-specific occupational licenses that can be difficult to transfer. Service members are also more likely to report financial struggles in states with higher-than-average unemployment rates, such as Louisiana, Alaska, and New York. Conversely, the state unemployment rate is below average in 9 of the 10 states where service members report the least financial difficulty. This suggests that strong local employment opportunities, particularly for spouses, significantly ease the financial burden on military households. Photo Credit: Bumble Dee / Shutterstock One of the most impactful ways to support service members, veterans, and their families who are facing financial hardships is through donations to reputable charities. These organizations are dedicated to addressing the unique challenges faced by military families and veterans, providing vital assistance in areas like housing, medical expenses, scholarships, and career training. To help guide your generosity, we’ve compiled a list of top-rated charities based on scores from Charity Navigator , CharityWatch , and GuideStar , which assess organizations on criteria such as impact, efficiency, accountability, and transparency. Here are some of the best charities supporting military families and veterans in need: 1. USO For over 80 years, the USO has provided crucial support to active-duty service members and their families. From financial assistance programs to community-building initiatives, the USO helps service members stay connected to loved ones while addressing their most pressing needs during deployments and transitions. 2. Homes For Our Troops This charity is focused on providing specially adapted homes for severely injured post-9/11 veterans. It helps veterans regain independence. Homes For Our Troops also provides financial planning and household budgeting to ensure long-term stability for the recipients. 3. Iraq and Afghanistan Veterans of America (IAVA) Dedicated to advocating for veterans of the Iraq and Afghanistan wars, IAVA works to improve government policies and programs that support military families. Its advocacy ensures veterans have access to financial resources, healthcare, and education opportunities. 4. Fisher House Foundation This foundation builds “comfort homes” near military and VA medical centers, allowing families to stay free of charge while a loved one is hospitalized. By reducing travel and lodging expenses, Fisher House eases financial stress during difficult times. 5. Hope For The Warriors Offering a range of programs focused on financial stability, wellness, social support, and education, Hope For The Warriors provides critical support to service members, veterans, and their families. Its services include direct financial assistance for transitioning service members and veterans in need, career training and job placement, and scholarships for spouses. 6. Semper Fi & America’s Fund Semper Fi & America’s Fund assists wounded, ill, and injured service members and their families through direct financial assistance and case management during hospitalization and recovery. The organization also provides educational support, career assistance, and health and wellness services. 7. Wounded Warriors Family Support (WWFS) WWFS supports families of those wounded or killed in combat through programs like medical travel grants, meal and housekeeping assistance, in-home care services, and family retreats. By addressing these families' immediate and ongoing needs, WWFS alleviates the financial burdens of those suffering from recent tragic events. For more information, a detailed methodology, and complete results, see Rising Costs Hit Military Families Hard: Here’s How You Can Help on Upgraded Points . Photo Credit: Jacob Lund / Shutterstock Upgraded Points conducted the analysis using the latest data from the U.S. Census Bureau Household Pulse Survey Phase 4.0–4.2 , covering the period from January 9, 2024, to September 16, 2024. Service members were defined as adults currently serving in the U.S. armed forces (Active Duty, Reserve, or National Guard) and their spouses. This analysis focuses on 3 key questions from the survey: Statistics with fewer than 50 survey responses were omitted from the analysis. Additional statistics on home prices were sourced from Zillow’s Home Value Index , and unemployment rates were sourced from the U.S. Census Bureau’s 2023 American Community Survey 1-Year Estimates . For complete results, see Rising Costs Hit Military Families Hard: Here’s How You Can Help on Upgraded Points. We're always interested in hearing about news in our community. Let us know what's going on! Get local news delivered to your inbox!

Sikh high priests stare at example of Gurbachan Singh

Sandstorm Gold Royalties Provides Updates on Producing and Key Development Assets

ph777 bet

Related articles:
Latest News
Recommended Reading
Hot Recommendations
jollibee 6 pcs www jilibet.com

Copyright © 2015 jilibet slots All Rights Reserved.